Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose.
3 months after end of treatment
Yes
Wilfried De Neve, MD, PhD
Principal Investigator
University Hospital, Ghent
Belgium: Institutional Review Board
2007/010
NCT00528294
February 2007
September 2013
Name | Location |
---|